Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation on Sangamo Therapeutics and its much-anticipated peek at results from a genome-editing trial. Then we talk about President Trump’s plan to change how often public companies have to spill their guts and what it could mean for biotech. Greg Yap, a partner at Menlo Ventures, joins us to dish on the red flags that dissuade him from a potential biotech investment, and we embark on a lightning round with appearances by bad cholesterol, CAR-T, and a diagnostic menstrual pad.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy